[ad_1]
ANVS401 interim clinical data demonstrate statistically significant improvements in cognitive function in AD patients and motor function in PD patients
Biomarkers demonstrate reduction in neurotoxic proteins, improved axonal health and reduced levels of inflammation
Next reading of clinical data expected in the third trimester
Berwyn, Pa .– (Newsfile Corp. – July 30, 2021) – Annovis Bio, Inc. (NYSE American: ANVS), a clinical-stage pharmaceutical platform company treating Alzheimer’s disease (AD), Parkinson’s (PD) and other neurodegenerative diseases, today expressed satisfaction with the positive interim results released July 28 from phase II clinical trials of its lead compound, ANVS401 (Posiphen).
During the first 25 days of treatment, the initial cohorts of patients demonstrated statistically significant positive results in both their cognitive and motor skills. The biomarkers presented and analyzed to date also support the efficacy of ANVS401.
Maria L. Maccecchini, Ph.D., Founder, CEO and President of Annovis Bio, said: “We were delighted to see improvements in cognition and motor skills in just 25 days and we hope to see positive results. cumulative and sustainable. from the use of ANVS401 until the remainder of the tests. “
Additional results include:
-
Patients with AD: In the ongoing ADAS-Cog study, the ANVS401 treated group showed improvement in all four ADAS-Cog tests performed compared to the placebo group. Specifically, the patients treated with ANVS401 showed a 4.7 point or 30% improvement while the placebo group showed a 1.1 point improvement in ADAS-Cog11. Additionally, the WAIS coding test, which measures speed of movement and thinking, found that treated AD patients had a 6.6 point improvement in coding after ANVS401 treatment. In patients with AD, there were positive trends in the MMSE and the total CDR score, but the data were not statistically significant.
-
Parkinsonian patients: In the current study of the MDS-UPDRS test, the group treated with ANVS401 showed improvement in all four parts of the UPDRS test compared to the placebo group. Specifically, Parkinson’s patients treated with ANVS401 improved by 6.2 points (14%), while the placebo group decreased by 4.2 points. Additionally, the WAIS coding test, which measures speed of movement and thinking, showed that PD patients had a 6.1 point improvement in coding after ANVS401 treatment.
The trial also measured the levels of six neurotoxic aggregation proteins, the lumen levels of neurofilaments to show axonal health, and three inflammatory markers that are prevalent in the brains of patients with AD and PD. All neurotoxic proteins were reduced in AD patients – some reductions were statistically significant and some were not. The lumen of neurofilaments was reduced in patients with AD and PD compared to placebo, although the results were not statistically significant. All inflammatory markers showed statistically significant reductions after 25 days of treatment in 14 PD patients. Additionally, we determined that there was a statistically significant increase in the Aβ42 / Aβ40 ratio in patients with AD, suggesting that they improved.
The company is awaiting its next clinical data read in the third quarter and plans to release the results of its review of all biomarkers in the toxic cascade in the coming months.
About Annovis Bio Inc.
Based in Berwyn, Pa., Annovis Bio, Inc. (Annovis) is a clinical stage pharmaceutical platform company dealing with neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease and Down syndrome (AD-DS). We believe that we are the only company to develop a drug for AD, PD and AD-AD that inhibits more than one neurotoxic protein and thus improves the nerve cell’s information highway known as transport. axonal. When this flow of information is disrupted, the nerve cell becomes ill and dies. We have two ongoing Phase 2 studies: one in patients with AD and one in patients with AD and PD. In the AD / PD study, our drug improves memory loss and dementia associated with AD, as well as bodily and brain functions in PD. For more information about Annovis, please visit the company’s website: www.annovisbio.com.
Forward-looking statements
The statements contained in this press release contain “forward-looking statements” which are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate”, “expect”, “believe”, “will”, “could”, “should”, “estimate” , “Plan”, ““ outlook ”,“ forecast ”or other similar terms, and include, without limitation, statements regarding the timing, efficacy and expected results of ANVS401 clinical trials. Forward-looking statements are based on current expectations of Annovis Bio, Inc. and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.In addition, certain forward-looking statements are based on assumptions about future events which may not prove to be correct. These and other risks and uncertainties are described in more detail in the section entitled “Risk Factors” of the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. assumes no obligation to update such information, except as required by applicable law.
Contacts
Investor Relations:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
[email protected]
Media:
Against Devin Broda / Kate Gorgi
Sard Verbinnen & Co
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91701
Source link
